Transition state analogue inhibitors of N-ribosyltransferases: new drugs by targeting nucleoside processing enzymes.

Gary B. Evans, Richard H. Furneaux, Peter M. Kelly, Vern L. Schramm, Peter C. Tyler

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The characterization of the transition state structure of a number of N-ribosyltransferases has enabled the design and synthesis of some extremely powerful inhibitors of these enzymes. We have three generations of inhibitors for some nucleoside processing enzymes which are therapeutic targets, and the potency of these compounds confers special advantages in their development as new drugs against cancer, autoimmune diseases, microbial infections and malaria.

Original languageEnglish (US)
Pages (from-to)63-64
Number of pages2
JournalNucleic acids symposium series (2004)
Issue number51
StatePublished - 2007
Externally publishedYes

Fingerprint

Enzyme Inhibitors
Drug Delivery Systems
Nucleosides
Autoimmune Diseases
Malaria
Enzymes
Infection
Pharmaceutical Preparations
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Transition state analogue inhibitors of N-ribosyltransferases : new drugs by targeting nucleoside processing enzymes. / Evans, Gary B.; Furneaux, Richard H.; Kelly, Peter M.; Schramm, Vern L.; Tyler, Peter C.

In: Nucleic acids symposium series (2004), No. 51, 2007, p. 63-64.

Research output: Contribution to journalArticle

@article{81097e05cc9f4513bb37e5307f1b174d,
title = "Transition state analogue inhibitors of N-ribosyltransferases: new drugs by targeting nucleoside processing enzymes.",
abstract = "The characterization of the transition state structure of a number of N-ribosyltransferases has enabled the design and synthesis of some extremely powerful inhibitors of these enzymes. We have three generations of inhibitors for some nucleoside processing enzymes which are therapeutic targets, and the potency of these compounds confers special advantages in their development as new drugs against cancer, autoimmune diseases, microbial infections and malaria.",
author = "Evans, {Gary B.} and Furneaux, {Richard H.} and Kelly, {Peter M.} and Schramm, {Vern L.} and Tyler, {Peter C.}",
year = "2007",
language = "English (US)",
pages = "63--64",
journal = "Nucleic acids symposium series (2004)",
issn = "1746-8272",
publisher = "Oxford University Press",
number = "51",

}

TY - JOUR

T1 - Transition state analogue inhibitors of N-ribosyltransferases

T2 - new drugs by targeting nucleoside processing enzymes.

AU - Evans, Gary B.

AU - Furneaux, Richard H.

AU - Kelly, Peter M.

AU - Schramm, Vern L.

AU - Tyler, Peter C.

PY - 2007

Y1 - 2007

N2 - The characterization of the transition state structure of a number of N-ribosyltransferases has enabled the design and synthesis of some extremely powerful inhibitors of these enzymes. We have three generations of inhibitors for some nucleoside processing enzymes which are therapeutic targets, and the potency of these compounds confers special advantages in their development as new drugs against cancer, autoimmune diseases, microbial infections and malaria.

AB - The characterization of the transition state structure of a number of N-ribosyltransferases has enabled the design and synthesis of some extremely powerful inhibitors of these enzymes. We have three generations of inhibitors for some nucleoside processing enzymes which are therapeutic targets, and the potency of these compounds confers special advantages in their development as new drugs against cancer, autoimmune diseases, microbial infections and malaria.

UR - http://www.scopus.com/inward/record.url?scp=42949125466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42949125466&partnerID=8YFLogxK

M3 - Article

C2 - 18029587

AN - SCOPUS:42949125466

SP - 63

EP - 64

JO - Nucleic acids symposium series (2004)

JF - Nucleic acids symposium series (2004)

SN - 1746-8272

IS - 51

ER -